Table 1 Distribution of variables by BMI category (non-obese, obese, and severely obese women)
BMI <30.0 | BMI 30 to 34.9 | BMI ≥ 35.0 | ||
|---|---|---|---|---|
Number (%) | Number (%) | Number (%) | P-valuea | |
Age at diagnosis, years | <0.001 | |||
20 to 44 | 1,473 (34.2%) | 138 (14.6%) | 56 (13.0%) | |
45 to 54 | 1,599 (37.1%) | 284 (30.1%) | 153 (35.5%) | |
55 to 64 | 932 (21.6%) | 364 (38.5%) | 147 (34.1%) | |
65 to 76 | 303 (7.0%) | 159 (16.8%) | 75 (17.4%) | |
Median (percentiles 25 to 75) | 48 (42 to 56) | 56 (49 to 62) | 55 (49 to 62) | |
Menopausal status | <0.001 | |||
Postmenopausal | 1,737 (40.3%) | 631 (66.8%) | 293 (68.0%) | |
Premenopausal | 2,570 (59.7%) | 314 (33.2%) | 138 (32.0%) | |
Histology | 0.730 | |||
Ductal | 3,645 (84.6%) | 788 (83.4%) | 376 (87.2%) | |
Lobulillar | 385 (8.9%) | 93 (9.8%) | 32 (7.4%) | |
Mixed | 46 (1.1%) | 12 (1.3%) | 4 (0.9%) | |
Others | 230 (5.3%) | 52 (5.5%) | 19 (4.4%) | |
Unknown | 1 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
Histological grade | 0.054 | |||
1 | 384 (8.9%) | 81 (8.6%) | 34 (7.9%) | |
2 | 1,792 (41.6%) | 416 (44.0%) | 196 (45.5%) | |
3 | 1,823 (42.3%) | 381 (40.3%) | 187 (43.4%) | |
Unknown | 308 (7.1%) | 67 (7.1%) | 14 (3.2%) | |
Pathologic primary tumor size | <0.001 | |||
T1 | 2,192 (50.9%) | 423 (44.8%) | 179 (41.5%) | |
T2 | 1,948 (45.2%) | 485 (51.3%) | 232 (53.8%) | |
T3 | 167 (3.9%) | 37 (3.9%) | 20 (4.6%) | |
Nodes | 0.021 | |||
Negative | 2,278 (52.9%) | 487 (51.5%) | 198 (45.9%) | |
Positive | 2,029 (47.1%) | 458 (48.5%) | 233 (54.1%) | |
Estrogen receptor | 0.647 | |||
Negative | 1,398 (32.5%) | 321 (34.0%) | 137 (31.8%) | |
Positive | 2,899 (67.3%) | 623 (65.9%) | 291 (67.5%) | |
Unknown | 10 (0.2%) | 1 (0.1%) | 3 (0.7%) | |
Progesterone receptor | 0.199 | |||
Negative | 1,654 (38.4%) | 373 (39.5%) | 149 (34.6%) | |
Positive | 2,576 (59.8%) | 558 (59.0%) | 276 (64.0%) | |
Unknown | 77 (1.8%) | 14 (1.5%) | 6 (1.4%) | |
Human epidermal growth factor-2 status | 0.030 | |||
Negative | 3,036 (70.5%) | 690 (73.0%) | 329 (76.3%) | |
Positive | 656 (15.2%) | 123 (13.0%) | 51 (11.8%) | |
Unknown | 615 (14.3%) | 132 (14.0%) | 51 (11.8%) | |
Type of surgery | 0.071 | |||
Mastectomy | 2,021 (46.9%) | 405 (42.9%) | 195 (45.2%) | |
Conservative | 2,286 (53.1%) | 540 (57.1%) | 236 (54.8%) | |
Hormonotherapy | 0.334 | |||
None | 1,068 (24.8%) | 256 (27.1%) | 115 (26.7%) | |
Yes | 3,081 (71.5%) | 664 (70.3%) | 300 (69.6%) | |
Unknown | 158 (3.7%) | 25 (2.6%) | 16 (3.7%) | |
Adverse events (grades 3,4) | 0.498 | |||
No | 2,565 (59.6%) | 578 (61.2%) | 250 (58.0%) | |
Yes | 1,742 (40.4%) | 367 (38.8%) | 181 (42.0%) | |
Initial under-treatment (in the first dose) b | <0.001 | |||
No | 4,205 (97.6%) | 922 (97.6%) | 405 (94.0%) | |
Yes | 102 (2.4%) | 23 (2.4%) | 26 (6.0%) | |
Per type of treatmentc | ||||
Epirubicin <85% | 5 (0.5%) | 5 (2.3%) | 4 (4.0%) | 0.002 |
Cyclophosphamide <85% | 12 (0.3%) | 4 (0.4%) | 8 (1.9%) | <0.001 |
Fluorouracil <85% | 8 (0.2%) | 4 (0.5%) | 7 (2.2%) | <0.001 |
Doxorubicin <85% | 4 (0.1%) | 3 (0.4%) | 7 (2.1%) | <0.001 |
Docetaxel <85% | 24 (2.5%) | 5 (2.4%) | 6 (5.4%) | 0.199 |
Paclitaxel <85% | 62 (5.2%) | 11 (4.2%) | 7 (6.7%) | 0.604 |
Overall undertreatment b | <0.001 | |||
No | 3,903 (90.6%) | 820 (86.8%) | 360 (83.5%) | |
Yes | 404 (9.4%) | 125 (13.2%) | 71 (16.5%) | |
Per type of treatment c | ||||
Epirubicin <85% | 50 (5.5%) | 15 (6.8%) | 13 (13.1%) | 0.011 |
Cyclophosphamide <85% | 213 (4.9%) | 49 (5.2%) | 34 (7.9%) | 0.032 |
Fluorouracil <85% | 132 (3.9%) | 25 (3.4%) | 24 (7.5%) | 0.005 |
Doxorubicin <85% | 160 (4.7%) | 40 (5.5%) | 26 (7.8%) | 0.040 |
Docetaxel <85% | 117 (15.8%) | 39 (18.9%) | 10 (9.9%) | 0.068 |
Paclitaxel <85% | 159 (13.3%) | 59 (22.6%) | 26 (25.0%) | <0.001 |